Generic Name

methYLphenidate

Brand Names
Relexxii, methYLphenidate Transdermal, Daytrana, Ritalin, Jornay, Quillivant, Metadate, Methylin, QuilliChew, Concerta, Cotempla, Aptensio
FDA approval date: December 31, 1955
Classification: Central Nervous System Stimulant
Form: Patch, Tablet, Suspension, Capsule, Solution

What is Relexxii (methYLphenidate)?

Methylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder , in pediatric patients 6 to 12 years of age. Methylphenidate hydrochloride extended-release capsule is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder in pediatric patients 6 to 12 years of age .
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)

Summary: Apathy is a common, early, and disabling symptom in dementias and mild behavioural impairment such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a tr...

The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Summary: The purpose of this study is to investigate the Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular Factors

Benefits of In-prison OROS-methylphenidate vs. Placebo Treatment in Detained People With Attention-deficit/Hyperactivity Disorder: A Randomized Controlled Trial

Summary: Attention deficit hyperactivity disorder (ADHD) is characterized by difficulties paying attention, poor impulse control, and hyperactive behaviors. It is associated with several health and social detrimental outcomes and leads to increased risks of criminality and recidivism. However, to date, ADHD treatment has been neglected in prison. This project will test the efficacy of ADHD treatment using ...

Brand Information